An essential element in cancer therapy is to inhibit the blood supply to the tumor. In this chapter, we discuss the few tyrosine phosphorylation inhibitors (tyrphostins/PTK inhibitors) that have been developed to achieve that goal. The inhibitors that block VEGFR2, PDGFR and EGFR and not solely VEGFR2 seem to do a better job towards this end. It is, however, not entirely clear that the anti-tumor effects observed with the agents described are entirely due to their antiangiogenic effects. This is because of the many other targets within the kinome they hit, which may be part of the oncogenic network, driving the cancers for which they were approved. None of the agents is life saving.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. Levitzki. in Faseb J 1992;3275–82.
A. Levitzki and E. Mishani. in Annu Rev Biochem 2006; 93–109.
R. L. Levine and D. G. Gilliland. in Curr Opin Hematol 2007;43–7.
S. Banai, S. D. Gertz, L. Gavish, M. Chorny, L. S. Perez, G. Lazarovichi, M. Ianculuvich, M. Hoffmann, M. Orlowski, G. Golomb and A. Levitzki. in Cardiovasc Res 2004;165–71.
M. C. Heinrich, C. L. Corless, C. D. Blanke, G. D. Demetri, H. Joensuu, P. J. Roberts, B. L. Eisenberg, M. von Mehren, C. D. Fletcher, K. Sandau, K. McDougall, W. B. Ou, C. J. Chen and J. A. Fletcher. in J Clin Oncol 2006;4764–74.
F. Winkler, S. V. Kozin, R. T. Tong, S. S. Chae, M. F. Booth, I. Garkavtsev, L. Xu, D. J. Hicklin, D. Fukumura, E. di Tomaso, L. L. Munn and R. K. Jain. in Cancer Cell 2004;553–63.
R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin and R. K. Jain. in Cancer Res 2004;3731–6.
L. M. Strawn, G. McMahon, H. App, R. Schreck, W. R. Kuchler, M. P. Longhi, T. H. Hui, C. Tang, A. Levitzki, A. Gazit, I. Chen, G. Keri, L. Orfi, W. Risau, I. Flamme, A. Ullrich, K. P. Hirth and L. K. Shawver. in Cancer Res 1996;3540–5.
S. J. Boyer. in Curr Top Med Chem 2002;973–1000.
P. W. Manley, G. Martiny-Baron, J. M. Schlaeppi and J. M. Wood. in Expert Opin Investig Drugs 2002;1715–36.
D. W. Davis, H. Q. Xiong, R. S. Herbst, J. L. Abbruzzese, J. V. Heymach, G. D. Demetri, W. Stadler and D. J. McConkey. in Proc Am Assoc Cancer Res 2004;Abstract #3988 P.
D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, L. J. Murray, J. Carver, E. Chan, K. G. Moss, J. O. Haznedar, J. Sukbuntherng, R. A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon and J. M. Cherrington. in Clin Cancer Res 2003;327–37.
J. Motzer, B. I. Rini, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. M. Bukowski, D. J. George, S. T. Kim and B. C.M. in ASCO Annual Meeting 2005;16 S, 4508R.
C. Blanke. in Clin Adv Hematol Oncol 2006;582–3.
W. P. Steward, A.Thomas, B. Morgan, B. Wiedenmann, C. Bartel, U. Vanhoefer, T. Trarbach, U. Junker, D. Laurent and D. Lebwohl. in J Clin Oncol 2004;3556.
B. Escudier, C. Szczylik and T. Eisen. in Proc Am Soc Clin Oncol 2005;380s Abstract LBA4510.
H. Richly, B. F. Henning, P. Kupsch, K. Passarge, M. Grubert, R. A. Hilger, O. Christensen, E. Brendel, B. Schwartz, M. Ludwig, C. Flashar, R. Voigtmann, M. E. Scheulen, S. Seeber and D. Strumberg. in Ann Oncol 2006;866–73.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Levitzki, A. (2008). Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents. In: Figg, W.D., Folkman, J. (eds) Angiogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-71518-6_31
Download citation
DOI: https://doi.org/10.1007/978-0-387-71518-6_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-71517-9
Online ISBN: 978-0-387-71518-6
eBook Packages: MedicineMedicine (R0)